Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | PRLHR | P49683 | 2/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | CLPP | Q16740 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440464 | 0.92 | ACHE (0.49) | ACHEHDAC1HDAC6MTORPRKCI | |
| SCHEMBL15440686 | 0.91 | ACHE (0.49) | ACHEMTORP2RX3TLR9OPRD1 | |
| SCHEMBL18303742 | 0.90 | ESR2 (0.45) | ACHEHDAC1HDAC6MTORC5AR1 | |
| SCHEMBL4318911 | 0.83 | ALDH1A1 (0.48) | PDE10AMTORPRLHRMAPTESR2 | |
| SCHEMBL4311781 | 0.82 | MTOR (0.41) | MTORESR2 | |
| SCHEMBL8513207 | 0.82 | PDE10A (0.55) | PDE10AMTORPRKCIMAPT | |
| SCHEMBL31138548 | 0.82 | PRLHR (0.39) | HDAC1HDAC6PDE10AMTORC5AR1 | |
| SCHEMBL31246456 | 0.81 | MAPT (0.42) | HDAC1HDAC6PDE10AMTORC5AR1 | |
| SCHEMBL16915795 | 0.81 | ACHE (0.46) | ACHETLR9LMNASTS | |
| SCHEMBL15440295 | 0.81 | VCP (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-2875018-B1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2018-02-14 | — | — | EP | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| EP-3208270-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-9475824-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062026-B2 | Fused pyrimidines and substituted quinazolines as inhibitors of p97 | CLEAVE BIOSCIENCES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258795-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | ACHE 4363/4885HDAC1 1262/4885HDAC6 599/4885 |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | PSMG3, PSMD1, PSMD3 | ACHE 3841/4885HDAC1 1403/4885HDAC6 336/4885 |
| US-20150239907-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | PSMG3, PSME1, PSMB1 | ACHE 4363/4885HDAC1 1262/4885HDAC6 599/4885 |
| US-10010554-B2 | Fused pyrimidines as inhibitors of P97 complex | PSMG3, PSME1, PSMB1 | ACHE 4363/4885HDAC1 1262/4885HDAC6 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.